Briefing
Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.
ctDNA dynamics were measured by droplet digital PCR in 69 people with metastatic uveal melanoma treated with tebentafusp.
- Design: Evidence level 3
- Assay: ddPCR
Nature CommunicationsPubMed 39402032DOI 10.1038/s41467-024-53145-0